Clearance for point-of-care haemoglobin analyser

EKF Diagnostics has announced US Food and Drug Administration (FDA) clearance for its hand-held, reagent-free haemoglobin analyser, the DiaSpect Tm, for use in point-of-care (POC) testing.

The DiaSpect Tm provides users with accurate haemoglobin measurements (precision: CV ≤1%) within two seconds of its whole blood-filled cuvette being inserted for analysis. This ensures immediate and robust haemoglobin results for patient health checks and anaemia screening at the point of care.

Based on its FDA categorisation, DiaSpect Tm can be used in various settings, as well as by a wide range of healthcare personnel. It is user-friendly and requiries minimal training. The user simply collects a capillary or venous blood sample of 10 µL in the cuvette before inserting into the analyser. Also making it simple for POC testing use, DiaSpect Tm is factory calibrated against the HiCN reference method in accordance with the International Council for Standardization in Haematology (ICSH). It is ‘always on’ and ready to use, with no re-calibration or maintenance necessary.

www.ekfdiagnostics.com

 

Other news

Upcoming Events

Update Course in Gynaecological Cytology

London Regional Cytology Training Centre, Level 6X, St Marks Building, Watford Road, Harrow HA1 3UJ
12-14 December 2018

Managing Cultural Differences in the Workplace

The Holiday Inn - Kensington Forum, 97 Cromwell Road, London SW7 4DN
21 January 2019

British Society for Haematology Paediatric Symposium

Royal College of Paediatrics and Child Health, 5-11 Theobalds Road, London WC1X 8SH
14 February 2019

Challenges in the clinical biochemistry laboratory and beyond

The Royal College of Pathologists
28 February 2019

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Dec 2018

Molecular diagnostics and LAMP technology

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.